According to Crawford et al. (2009), CAFs play a critical role in the resistance to anti-angiogenesis therapy because PDGF expression is also positively regulated in tumour CAFs that are resistant to anti-VEGF therapy and administration of a PDGF-neutralizing antibody was able to change this anti-VEGF resistance (Figure 6). The gene discussed is VEGFA; the disease is neoplasm.